A Prospective, Multicenter Study Investigating Reherniation Risk Factors and Associated Costs in Primary Lumbar Disc Herniation Patients

Status: Active_not_recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The purpose of this 12-month, prospective, multicenter study is to investigate the effect of annular defect size and other risk factors on reherniation and associated costs in primary lumbar discectomy patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 75
Healthy Volunteers: f
View:

• Age 21 to 75 years old and skeletally mature (male or female).

• Patients with posterior or posterolateral disc herniations at one level between L1 and S1 with radiographic confirmation of neural compression using MRI. \[Note: Intraoperatively, only patients with an annular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.\]

• Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees)22 (L45, L5S1) or Femoral Stretch Test (L12, L23, L34)

• Oswestry Questionnaire score of at least 40/100 at baseline.

• VAS leg pain (one or both legs) of at least 40/100 at baseline.

• Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.

• Minimum posterior disc height of 5mm at the index level.

Locations
United States
Illinois
Midwest Orthopaedics at Rush Medical Center
Chicago
Kansas
Orthopaedic Specialists Of The Four States
Galena
Kentucky
Orthopaedic Institute of Western Kentucky
Paducah
Michigan
Michigan Orthopedic Specialists
Dearborn
Time Frame
Start Date: 2016-02-17
Completion Date: 2025-03
Participants
Target number of participants: 100
Treatments
Small annular defect group
Patients with lumbar defect less than 6mm wide after lumbar discectomy
Large annular defect group
Patients with lumbar defect greater than 6mm wide after lumbar discectomy
Authors
Related Therapeutic Areas
Sponsors
Leads: Intrinsic Therapeutics

This content was sourced from clinicaltrials.gov